| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_55f8b4a24fa698ac5171923c274ca5ac |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-804
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-806
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-807
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-864 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-531
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 |
| filingDate |
1986-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1988-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffffaf4f3055a09b4d2e9a54bac83e03 |
| publicationDate |
1988-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-1239355-A |
| titleOfInvention |
Antibody hybrid molecules and process for their preparation |
| abstract |
ANTIBODY HYBRID MOLECULES AND PROCESS FOR THEIR PREPARATION ABSTRACT OF THE DISCLOSURE Antibodies which contain reduced sulfhydryl groups in proximity to the carboxyl terminal end of their heavy chain are coupled to another moiety which has an available sulfhydryl for forming a disulfide bond with the antibodies. IgM is a typical antibody which contains a suitable structure by virtue of its cysteine residue in proximity to the carboxyl terminal end of its heavy chain. A typical hybrid is formed with IgM and the A chain of a toxin such as ricin by the formation of a covalent disulfide bond therebetween. Use of antibodies having structures such as IgM result in hybrid formation in which the moiety joined to the antibody is site directed with respect to its bonding location on the antibody. Such hybrids have utility including in vivo therapeutic applications in which the functionality of the antibody is not deleteriously im-paired by the moiety bonded thereto. |
| priorityDate |
1985-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |